ARTICLE | Clinical News
Mesenchymal precursor cells: Phase III start
November 11, 2013 8:00 AM UTC
By year end, Mesoblast said Teva will begin a double-blind, placebo-controlled, international Phase III trial to evaluate a single dose of 150 million MPCs delivered via transendocardial injection cat...